Enliven Therapeutics (ELVN) Cash from Investing Activities (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Cash from Investing Activities data on file, last reported at $42.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 2880.1% year-over-year to $42.5 million; the trailing twelve-month figure through Mar 2026 stood at -$132.7 million (down 695.58% YoY), and the FY2025 full-year result was -$173.8 million, down 382.93% from the prior year.
• Cash from Investing Activities advanced to $42.5 million in Q1 2026, from $12.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $42.5 million in Q1 2026 to a low of -$183.6 million in Q2 2025.
• A 5-year average of -$18.6 million and a median of -$101000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 38402.97% in 2023, while the deepest fall reached 253821.43% in 2023.
• Tracing ELVN's Cash from Investing Activities over 5 years: stood at -$101000.0 in 2022, then soared by 38402.97% to $38.7 million in 2023, then sank by 98.12% to $727000.0 in 2024, then jumped by 1602.75% to $12.4 million in 2025, then jumped by 243.53% to $42.5 million in 2026.
• Business Quant data shows ELVN's Cash from Investing Activities at $42.5 million in Q1 2026, $12.4 million in Q4 2025, and -$4.1 million in Q3 2025.